title: Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential.
abstract: Programmed cell death ligand 1 (PDL1) expression was recently shown to correlate with tumor-infiltrating lymphocytes (TILs) in a subset of osteosarcoma patients. Among clinical factors evaluated across human osteosarcoma samples, a pulmonary origin of metastases correlated with high PDL1 expression and prominent TILs. Considering that multiple agents targeting PD-1/PDL1 are under development, targeting this immune checkpoint may be a novel immunotherapeutic route for osteosarcoma in future clinical trials.
authors.affiliation: Sarcoma Biology Laboratory; Center for Sarcoma and Connective Tissue Oncology; Massachusetts General Hospital ; Boston, MA USA.
authors.forename: Jacson K
authors.initials: JK
authors.lastname: Shen
authors.affiliation: Division of Hematology and Oncology; Massachusetts General Hospital ; Boston, MA USA.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Cote
authors.affiliation: Division of Hematology and Oncology; Massachusetts General Hospital ; Boston, MA USA.
authors.forename: Edwin
authors.initials: E
authors.lastname: Choy
authors.affiliation: Sarcoma Biology Laboratory; Center for Sarcoma and Connective Tissue Oncology; Massachusetts General Hospital ; Boston, MA USA.
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Hornicek
authors.affiliation: Sarcoma Biology Laboratory; Center for Sarcoma and Connective Tissue Oncology; Massachusetts General Hospital ; Boston, MA USA.
authors.forename: Zhenfeng
authors.initials: Z
authors.lastname: Duan
keywords: PDL1; TILs; immunotherapy; mRNA; osteosarcoma